₹572.70 apiece as investors cheered the drug maker’s launch of an oral antiviral drug for treatment of covid-19 patients with mild to moderate symptoms.Glenmark Pharmaceuticals on Saturday launched antiviral drug favipiravir, under the brand name FabiFlu, for the treatment of covid-19 patients at a price of about ₹103 per tablet.
The drug will be available as a 200 mg tablet at a maximum retail price of ₹3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.
FabiFlu is the first oral favipiravir approved medication in India for the treatment of covid-19, it added.Analysts said it is very difficult to estimate the financial impact at this stage considering uncertainty over potential covid-19 patients and its longevity.